1. ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
- Author
-
Benzhi Cai, Shuainan Li, Fan Yang, Yan Xu, Binbin Xu, and Wenya Ma
- Subjects
Pharmacology ,Kidney ,Heart Injury ,Lung ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Clinical Biochemistry ,Protective factor ,COVID-19 ,Outbreak ,Bioinformatics ,Clinical research ,medicine.anatomical_structure ,Heart Injuries ,Cardiovascular Diseases ,Drug Discovery ,medicine ,Humans ,Molecular Medicine ,Angiotensin-Converting Enzyme 2 ,business ,Receptor ,hormones, hormone substitutes, and hormone antagonists - Abstract
ACE2 has long been known as an injury protective protein, which can protect against a variety of organ damage such as the heart, liver, kidney, and lung. Especially in cardiovascular diseases, as a negative regulator of RAAS, ACE2 is an extremely important protective factor that mainly plays a role by converting Ang II to Ang-(1-7). Nevertheless, with the recent outbreak of COVID-19, it is exposed that another identity of ACE2 is the entry receptor for SARS-CoV-2, which previously serves as the entry receptor for SARS. With the in-depth clinical research, it is found that the severity and susceptibility of COVID-19 are related to cardiovascular diseases, and SARS-CoV-2 binding to ACE2 receptor is also potentially associated with heart injury symptoms. Therefore, in this article, we mainly summarize the relationship between ACE2, COVID-19, and cardiovascular diseases/heart injury.
- Published
- 2021
- Full Text
- View/download PDF